Latest News and Press Releases

RALEIGH, N.C., Dec. 16, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced today that Richard A. Franco, Chief Executive Officer and President, is scheduled to present at the...

RALEIGH, N.C., Dec. 14, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced today additional positive results from its successfully completed KRN5500 Phase 2a Clinical Study for...

RALEIGH, N.C., Nov. 15, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA), a biopharmaceutical development company, today announced that the Company will present at the New York Society of...

RALEIGH, N.C., Nov. 11, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) today announced that a NASDAQ Listing Qualifications Panel (the "Panel") has granted the Company's request for an...

DB959 is a Highly Selective, Non-TZD First-In-Class Dual PPAR-Delta/Gamma Agonist DARA is Advancing Two Drugs From Its Portfolio Through Clinical Trials RALEIGH, N.C., Nov. 4, 2010 (GLOBE...

RALEIGH, N.C., Nov. 2, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences (Nasdaq:DARA) announced today grant approvals by the Internal Revenue Service under the Patient Protection and Affordable Care Act of...

RALEIGH, N.C., Oct. 25, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA), a development-stage pharmaceutical company, today announced that it has entered into a definitive agreement with...

RALEIGH, N.C., Sept. 8, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences (Nasdaq:DARA) announced today that it presented study results from its Phase 2 multicenter, placebo controlled, double-blind,...

RALEIGH, N.C., Sept. 1, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced today that Richard A. Franco, R.Ph., Chief Executive Officer and President, is scheduled to present at...

RALEIGH, N.C., Aug. 20, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced today that the company has been selected by the Scientific Program Committee to present at the Congress...